287 related articles for article (PubMed ID: 26611553)
1. Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Keller SF; Miloslavsky EM
Rheum Dis Clin North Am; 2016 Feb; 42(1):91-101, viii. PubMed ID: 26611553
[TBL] [Abstract][Full Text] [Related]
2. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.
Lally L; Spiera R
Rheum Dis Clin North Am; 2015; 41(1):1-19, vii. PubMed ID: 25399936
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
4. How best to manage relapse and remission in ANCA-associated vasculitis.
Puéchal X; Guillevin L
Expert Rev Clin Immunol; 2022 Nov; 18(11):1135-1143. PubMed ID: 36102147
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
6. Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis.
Berti A; Cornec D; Dua AB
Rheum Dis Clin North Am; 2023 Aug; 49(3):545-561. PubMed ID: 37331732
[TBL] [Abstract][Full Text] [Related]
7. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
Santana AN; Woronik V; Halpern AS; Barbas CS
J Bras Pneumol; 2011; 37(6):809-16. PubMed ID: 22241040
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
9. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
10. [Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis].
Holle JU; Hellmich B; Moosig F
Z Rheumatol; 2022 May; 81(4):280-285. PubMed ID: 35061059
[TBL] [Abstract][Full Text] [Related]
11. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
12. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
[TBL] [Abstract][Full Text] [Related]
13. Granulomatous Vasculitis.
Sharma A; Dogra S; Sharma K
Dermatol Clin; 2015 Jul; 33(3):475-87. PubMed ID: 26143427
[TBL] [Abstract][Full Text] [Related]
14. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.
Sada KE; Yamamura M; Harigai M; Fujii T; Takasaki Y; Amano K; Fujimoto S; Muso E; Murakawa Y; Arimura Y; Makino H;
Arthritis Res Ther; 2015 Nov; 17():305. PubMed ID: 26525413
[TBL] [Abstract][Full Text] [Related]
15. L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: different outcomes?
Holle JU
Presse Med; 2013 Apr; 42(4 Pt 2):616-9. PubMed ID: 23481358
[No Abstract] [Full Text] [Related]
16. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
17. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
18. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of ANCA-associated vasculitis.
Kronbichler A; Bajema IM; Bruchfeld A; Mastroianni Kirsztajn G; Stone JH
Lancet; 2024 Feb; 403(10427):683-698. PubMed ID: 38368016
[TBL] [Abstract][Full Text] [Related]
20. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice.
Chevet B; Cornec D; Casal Moura M; Cornec-Le Gall E; Fervenza FC; Warrington KJ; Specks U; Berti A
Rheumatology (Oxford); 2023 May; 62(5):1787-1803. PubMed ID: 36315063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
